Steve Aselage Sells 10,000 Shares of Retrophin Inc (NASDAQ:RTRX) Stock

Retrophin Inc (NASDAQ:RTRX) Director Steve Aselage sold 10,000 shares of Retrophin stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.00, for a total value of $200,000.00. Following the completion of the sale, the director now directly owns 238,732 shares of the company’s stock, valued at $4,774,640. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Steve Aselage also recently made the following trade(s):

  • On Thursday, May 14th, Steve Aselage sold 3,062 shares of Retrophin stock. The shares were sold at an average price of $15.09, for a total value of $46,205.58.
  • On Tuesday, May 12th, Steve Aselage sold 1,000 shares of Retrophin stock. The stock was sold at an average price of $17.16, for a total value of $17,160.00.

Shares of Retrophin stock opened at $20.41 on Wednesday. The firm has a market cap of $844.12 million, a price-to-earnings ratio of -8.33 and a beta of 0.81. The stock’s 50-day moving average is $16.32 and its 200-day moving average is $15.36. Retrophin Inc has a one year low of $8.98 and a one year high of $21.95. The company has a debt-to-equity ratio of 0.92, a current ratio of 5.97 and a quick ratio of 5.88.

Retrophin (NASDAQ:RTRX) last issued its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.70. The company had revenue of $47.77 million for the quarter, compared to analyst estimates of $43.14 million. Retrophin had a negative return on equity of 43.15% and a negative net margin of 57.01%. On average, equities analysts expect that Retrophin Inc will post -1.56 EPS for the current year.

Several institutional investors have recently modified their holdings of RTRX. Rhumbline Advisers lifted its holdings in shares of Retrophin by 10.5% in the fourth quarter. Rhumbline Advisers now owns 81,559 shares of the biopharmaceutical company’s stock valued at $1,158,000 after purchasing an additional 7,734 shares in the last quarter. Swiss National Bank raised its holdings in Retrophin by 6.6% during the fourth quarter. Swiss National Bank now owns 74,000 shares of the biopharmaceutical company’s stock worth $1,051,000 after acquiring an additional 4,600 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Retrophin by 0.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 340,511 shares of the biopharmaceutical company’s stock worth $4,836,000 after acquiring an additional 3,076 shares in the last quarter. Bank of Montreal Can raised its holdings in Retrophin by 11.8% during the fourth quarter. Bank of Montreal Can now owns 164,445 shares of the biopharmaceutical company’s stock worth $2,336,000 after acquiring an additional 17,344 shares in the last quarter. Finally, Mackay Shields LLC raised its holdings in Retrophin by 5.6% during the fourth quarter. Mackay Shields LLC now owns 80,500 shares of the biopharmaceutical company’s stock worth $1,143,000 after acquiring an additional 4,300 shares in the last quarter.

A number of brokerages recently commented on RTRX. BMO Capital Markets lifted their price objective on Retrophin from $33.00 to $34.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 12th. ValuEngine cut Retrophin from a “strong-buy” rating to a “buy” rating in a research note on Friday, April 17th. Zacks Investment Research cut Retrophin from a “buy” rating to a “hold” rating in a research note on Tuesday. Canaccord Genuity reaffirmed a “buy” rating and set a $26.00 price objective on shares of Retrophin in a research note on Tuesday, May 19th. Finally, BidaskClub raised Retrophin from a “hold” rating to a “buy” rating in a research note on Saturday. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Retrophin has an average rating of “Buy” and an average price target of $26.50.

About Retrophin

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Read More: What are different types of coverage ratios?

Insider Buying and Selling by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.